As Cheplapharm has no own production facilities, we consider our own environmental risk profile as low. The direct environmental footprint (e.g. Scope 1 and 2 GHG emissions, use of electricity, use of water) is considerably lower than for other companies in the pharmaceutical sector.
We are, however, aware that we bear responsibility for high environmental standards in our supply chain (pharmaceutical product manufacturing) and have thus started to gather comprehensive data from our suppliers. Based on the gathered data we plan to expand the existing supplier selection criteria and include minimum ESG requirements.
Of the suppliers who answered in our initial supplier survey1, 79%2 indicated having an environmental management system in place that complies to requirements laid out by EMAS or ISO 14001 (or equivalent). 64%3 measured CO2 emissions and production and 71%4 the amount of toxic emissions from pharmaceutical production. 93%5 also measured electricity and water consumption, while 57%6 used at least partly their own produced renewable energies.
At Cheplapharm, positive direct environmental impact can mostly be made by considering environmental factors in infrastructural projects. In recent years, at the company’s HQ in Greifswald a PV system was built and two EV charging spots installed.
1 Answers were received for a total buy volume of 30.82% as of 2020.
2 Corresponding to a total buy volume of 26.05%
3 Corresponding to a total buy volume of 20.50%
4 Corresponding to a total buy volume of 26.24%
5 Corresponding to a total buy volume of 30.38%
6 Corresponding to a total buy volume of 19.07%